



MINI REVIEW

Novel Concepts for Clinical Pharmacology from “Calcium Paradox” due to Neuronal Interaction between Signalling Pathways Mediated by Ca²⁺ and cAMP from 1975 to 2017

Leandro Bueno Bergantin* and Afonso Caricati-Neto

Department of Pharmacology, Federal University of Sao Paulo (UNIFESP), Brazil



*Corresponding author: Leandro Bueno Bergantin, Laboratory of Autonomic and Cardiovascular Pharmacology, Department of Pharmacology, Paulista School of Medicine, Federal University of Sao Paulo (UNIFESP), Rua Pedro de Toledo, 669-Vila Clementino, Sao Paulo-SP, Brazil, CEP: 04039-032, Tel: 55-11-5576-4973, E-mail: leanbio39@yahoo.com.br

Abstract

The solution for the so-called “calcium paradox” has been revealed 4 years ago, when we demonstrated the involvement of the interaction between Ca²⁺ and cAMP signalling pathways (Ca²⁺/cAMP signalling interaction) in this enigma. The “calcium paradox” emerged 4 decades ago, when numerous clinical studies have concluded that prescription of L-type Ca²⁺ Channel Blockers (CCBs) for hypertensive patients decreased arterial pressure, but produced stimulation of sympathetic hyperactivity. Indeed, initially these adverse effects of CCBs have been attributed to adjust reflex of arterial pressure, but this conclusion remained not completely satisfactory. The year of 2013 would change this history forever! Through an original experiment, we revealed that the “calcium paradox” phenomenon came from increased transmitter release from sympathetic neurons stimulated by CCBs due to its handling on the Ca²⁺/cAMP signalling interaction. It is now well-established that the signalling pathways mediated by Ca²⁺ and cAMP can interact, thus playing a vital role in cellular processes of mammals. In the clinical pharmacology, it has opened novel opportunities for the development of pharmaceuticals more efficient, and safer, for treating neurodegenerative diseases. Then, the manipulation of Ca²⁺/cAMP signalling interaction could improve therapeutic strategies for stimulating synaptic transmission compromised by transmitter release deficit, and attenuating death of neurons. More recently, the manipulation of this interaction has been proposed by us to inhibit cancer progression, another interesting avenue for medical research.

Keywords

Signalling pathways mediated by Ca²⁺ and cAMP, “Calcium paradox”, Neurology, Cancer

Introduction

Since the last decade, it has been shown that the signalling pathways mediated by Ca²⁺ and cAMP can interact (Ca²⁺/cAMP signalling interaction), thus playing a vital role in cellular processes of mammals. In the clinical pharmacology, the manipulation of this interaction could improve therapeutic strategies for stimulating synaptic transmission compromised by transmitter release deficit, and attenuating death of neurons. More recently, the manipulation of this interaction has been proposed by us to inhibit cancer progression. All this history initiated with the concept of the “calcium paradox”. It has been almost 4 years since we revealed the involvement of the Ca²⁺/cAMP signalling interaction in the enigma of the so-called “calcium paradox”. For understanding the “calcium paradox”, we should return to the past. Indeed, the concept of stimulus-secretion to elucidate neurotransmitters release has been achieved from creative experiments made by Douglas and Rubin in the 1960s [1]. By their concepts, in 1970's Baker and Knight showed that an increase in the cytosolic Ca²⁺ concentration ([Ca²⁺]_c) is a fundamental requirement to start transmitter release [2]. In addition, the unquestionable result showing a correlation between neurotransmitter release and elevation in [Ca²⁺]_c came from the interesting experiments made by the Nobel laureate Erwin Neher [3]. Thus, by reducing extracellular Ca²⁺ through blocking Ca²⁺ channels, we should have a reducing in the neurotransmitter release. None-

theless, many reports have demonstrated that L-type Ca^{2+} Channel Blockers (CCBs), in concentrations below $1 \mu\text{mol/L}$, could induce neurotransmitter release, a “paradox” [4-6]. In addition, many reports have demonstrated that cAMP enhances neurotransmitter release at several synapses in autonomic nervous system of mammals [7]. Recently, we demonstrated that Ca^{2+} /cAMP signalling interaction is implicated in the modulation of transmitters release from sympathetic neurons, and thus in the “calcium paradox” [8-11].

The Interaction between Ca^{2+} and cAMP Signalling Pathways as a Classical Concept: An Interesting History

It is well established that the interaction between Ca^{2+} and cAMP signalling pathways is as a vital cellular process in mammals [8-11]. This classical concept assumes that these signalling pathways virtually exist in all mammalian cells, modulated by Adenylyl Cyclases (ACs) and Phosphodiesterases (PDEs) [8-11]. In addition, En-

doplasmic Reticulum (ER) Ca^{2+} channels have particularly been a forefront for the interaction between Ca^{2+} and cAMP signalling pathways field, such as Ca^{2+} channels modulated by Ryanodine Receptors (RyR) [8-11]. We reinforced the idea that the interaction between Ca^{2+} and cAMP signalling pathways plays a fundamental participation in the modulation of neurotransmitter release from neurons and neuroendocrine cells [8-11]. Then, the interaction of Ca^{2+} and cAMP signalling pathways could be a new therapeutic goal for pharmaceuticals.

The Interaction between Ca^{2+} and cAMP Signalling Pathways and Clinical Pharmacology

The prescription of L-type CCBs in hypertensive patients has been reported to decrease arterial pressure, but also produces sympathetic hyperactivity [12]. Initially, these adverse effects of CCBs have been attributed to adjust reflex of arterial pressure, but this conclusion remained not completely satisfactory. The year of 2013 would change this history forever! Through a creative




Figure 1: Transmitter release stimulation and reduction of neuronal death triggered by Ca^{2+} overload can be achieved due to pharmacological regulation of the interaction between Ca^{2+} and cAMP signalling pathways. In response to the decreasing of Ca^{2+} influx through L-type voltage-activated Ca^{2+} channels produced by CCBs, the adenylyl cyclase activity (and consequently cAMP) is increased. These CCBs-effects can be stimulated by cAMP-enhancer compounds (like PDEs inhibitors). PDEs - Phosphodiesterases, RyR - Ryanodine Receptors, IP_3R - IP_3 Receptors, SERCA - Sarcoendoplasmic Reticulum Ca^{2+} -ATPase.

experiment, we revealed that the solution for this so-called “calcium paradox” phenomenon was due to the increase of transmitter release from sympathetic neurons achieved by CCBs due to its handling on the interaction between Ca^{2+} and cAMP signalling pathways [9]. We demonstrated that contractions of the smooth muscle (vas deferens) were completely inhibited by L-type CCBs in high concentrations ($> 1 \mu\text{mol/L}$), but puzzlingly increased in concentrations below $1 \mu\text{mol/L}$, thus defined as sympathetic hyperactivity promoted by CCBs [4-6,9]. Our studies clearly established that the contradictory sympathetic hyperactivity is due to an augmentation of transmitter release from sympathetic neurons achieved by L-type CCBs due to its interfering on the interaction between Ca^{2+} and cAMP signalling pathways.

In fact, many reports have shown that elevation of cytosolic cAMP concentration ([cAMP]c) reduces neuronal death resulted from cytosolic Ca^{2+} overload, stimulating neuroprotective effect [13,14]. As mentioned above, the L-type CCBs increase transmitter release due to its handling on the interaction between Ca^{2+} and cAMP signalling pathways. This interference activates ACs, causing elevation of [cAMP]c that, in turn, induces Ca^{2+} release from ER that stimulates transmitter release [8-11]. In addition, this elevation of [cAMP]c produces neuroprotective effects mediated by the Ca^{2+} and cAMP signalling pathways [8-11]. It was proposed that this neuroprotective effect results from activation by cAMP on the cellular survival pathways mediated by PKA/CREB [8-11,13,14]. Then, the pharmacological interfering of the Ca^{2+} /cAMP signalling interaction from the combined use of the L-type CCBs prescribed in the antihypertensive therapy, and [cAMP]c-enhancer compounds prescribed in the anti-depressive therapy like rolipram, could be a novel pharmacological goal for increasing neurotransmission in neurological and psychiatric disorders resulted from deficit of neurotransmitter release, and neuronal death [8-11]. Figure 1 illustrates how the pharmacological handling of the interaction between Ca^{2+} and cAMP signalling pathways could produce increase of neurotransmitter release, and attenuation of neuronal death.

In fact, it was showed that the prescription of L-type CCBs is able to reduce motor symptoms, and reduces the continued neuronal death in animal model of Parkinson's disease, indicating that L-type CCBs are potentially workable neuroprotective pharmaceuticals [15]. Intriguingly, a 1-decade study involving thousands senile hypertensive patients demonstrated that prescription of L-type CCBs can reduce blood pressure, and incidence of dementia in hypertensive patients, indicating that these pharmaceuticals could be used to treat neurodegenerative diseases in clinics [16]. These results for the effects related to neuroprotection of CCBs have been reinvestigated in thousands elderly hypertensive patients with dysfunction of memory abilities [17]. These studies concluded that patients who have taken CCBs

had their risk of cognitive dysfunction decreased, such as Alzheimer's disease [17]. These findings reinforce the concept that L-type CCBs can reduce cytosolic Ca^{2+} overload produced due to blocking of Ca^{2+} influx, and thus could be an alternative pharmacological goal to reduce, or prevent, death of neurons resulted from neurodegenerative diseases.

Based on these findings, we have anticipated that the pharmacological regulation of the Ca^{2+} /cAMP signalling interaction by combined use of the L-type CCBs and [cAMP]c-enhancer compounds could be a novel therapeutic goal for increasing neurotransmission in neurological, and psychiatric disorders, resulted from neurotransmitter release deficit and neuronal death [8-11]. This pharmacological strategy opens a novel pathway for the drug development more efficient for the treatment of Alzheimer's and other neurodegenerative diseases [11,18-23].

In addition, it has been shown that the dysregulation of intracellular signaling pathways mediated by Ca^{2+} and cAMP participates in the cancer initiation, tumor formation, tumor progression, metastasis, invasion and angiogenesis. Thereby, proteins involved in these pathways, such as Ca^{2+} channels and cAMP-dependent Protein Kinase (PKA), represent potential drugs targets for cancer therapy [24]. With this concept in mind, some studies showed that drugs able to interfere with the intracellular Ca^{2+} signaling such as selective CCBs, as amlodipine, inhibit proliferative response in different cancer cells [24-27]. In addition, drugs able to increase the intracellular cAMP levels (cAMP-enhancer compounds), such as Phosphodiesterase (PDE) 4 inhibitors, have been proposed as potential adjuvant, chemotherapeutic or chemopreventive agents in some cancer types, including hepatocellular carcinoma [28]. Then, the pharmacological modulation of the intracellular signaling mediated by Ca^{2+} and cAMP in the cancer cells may represent a new therapeutic strategy for cancer progression.

Conclusion

In conclusion, pharmacological interfering of the interaction between Ca^{2+} and cAMP signalling pathways could be a more efficient therapeutic approach for enhancing neurotransmission resulted from neurotransmitter release deficit, and reducing neuronal death in the neurodegenerative diseases (like Alzheimer's and Parkinson's diseases). More recently, the manipulation of this interaction has been proposed by us to inhibit cancer progression, another avenue for medical research. These findings could dramatically impact in clinical pharmacology.

Disclosure Statement

Caricati-Neto and Bergantin thank the continued financial support from CAPES, CNPq and FAPESP (Bergantin's Postdoctoral Fellowship FAPESP #2014/10274-3).

The authors also thank Elsevier - "author use":

Reuse of portions or extracts from the article in other works - https://www.elsevier.com/_data/assets/pdf_file/0007/55654/AuthorUserRights.pdf.

References

- Douglas WW, Rubin RP (1961) The role of calcium in the secretory response of the adrenal medulla to acetylcholine. *J Physiol* 159: 40-57.
- Baker PF, Knight DE (1978) Calcium-dependent exocytosis in bovine adrenal medullary cells with leaky plasma membranes. *Nature* 276: 620-622.
- Neher E, Zucker RS (1993) Multiple calcium-dependent processes related to secretion in bovine chromaffin cells. *Neuron* 10: 21-30.
- Kreye VA, Lüth JB (1975) Proceedings: Verapamil-induced phasic contractions of the isolated rat vas deferens. *Naunyn Schmiedebergs Arch Pharmacol* 287: 43.
- French AM, Scott NC (1981) A comparison of the effects of nifedipine and verapamil on rat vas deferens. *Br J Pharmacol* 73: 321-323.
- Moritoki H, Iwamoto T, Kanaya J, Maeshiba Y, Ishida Y, et al. (1987) Verapamil enhances the non-adrenergic twitch response of rat vas deferens. *Eur J Pharmacol* 140: 75-83.
- Chern YJ, Kim KT, Slakey LL, Westhead EW (1988) Adenosine receptors activate adenylate cyclase and enhance secretion from bovine adrenal chromaffin cells in the presence of forskolin. *J Neurochem* 50: 1484-1493.
- Caricati-Neto A, García AG, Bergantin LB (2015) Pharmacological implications of the Ca²⁺/cAMP signalling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. *Pharmacol Res Perspect* 3: e00181.
- Bergantin LB, Souza CF, Ferreira RM, Smaili SS, Jurkiewicz NH, et al. (2013) Novel model for "calcium paradox" in sympathetic transmission of smooth muscles: role of cyclic AMP pathway. *Cell Calcium* 54: 202-212.
- Bergantin LB, Jurkiewicz A, García AG, Caricati-Neto A (2015) A Calcium Paradox in the Context of Neurotransmission. *Journal of Pharmacy and Pharmacology* 3: 253-261.
- Bergantin LB, Caricati-Neto A (2016) Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca²⁺/cAMP intracellular signalling interaction. *Eur J Pharmacol* 788: 255-260.
- Grossman E, Messerli FH (1998) Effect of calcium antagonists on sympathetic activity. *Eur Heart J* 19: 27-31.
- Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, et al. (1995) The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. *Nat Med* 1: 244-248.
- Xiao L, O'Callaghan JP, O'Donnell JM (2011) Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. *J Pharmacol Exp Ther* 338: 641-647.
- Ilijic E, Guzman JN, Surmeier DJ (2011) The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. *Neurobiol Dis* 43: 364-371.
- Wu CL, Wen SH (2016) A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients. *Medicine (Baltimore)* 95: e4593.
- Hanon O, Pequignot R, Seux ML, Lenoir H, Bune A, et al. (2006) Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. *J Hypertens* 24: 2101-2107.
- Bergantin LB, Caricati-Neto A (2016) Insight from "Calcium Paradox" due to Ca²⁺/cAMP Interaction: Novel Pharmacological Strategies for the Treatment of Depression. *Int Arch Clin Pharmacol* 2: 007.
- Bergantin LB, Caricati-Neto A (2016) Novel Insights for Therapy of Parkinson's disease: Pharmacological Modulation of the Ca²⁺/cAMP Signalling Interaction. *Austin Neurol & Neurosci* 1: 1009.
- Bergantin LB, Caricati-Neto A (2016) Recent advances in pharmacotherapy of neurological and psychiatric disorders promoted by discovery of the role of Ca²⁺/cAMP signaling interaction in the neurotransmission and neuroprotection. *Adv Pharmacol* 1: 66-70.
- Bergantin LB, Caricati-Neto A (2016) From discovering "calcium paradox" to Ca²⁺/cAMP interaction: Impact in human health and disease. *J Tissue Sci Eng* 7: 3.
- Caricati-Neto A, Bergantin LB (2016) New therapeutic strategy of Alzheimer's and Parkinson's diseases: Pharmacological modulation of neural Ca²⁺/cAMP intracellular signaling interaction. *Asian Journal of Pharmacy and Pharmacology* 2: 136-143.
- Bergantin LB, Caricati-Neto A (2016) Impact of interaction of Ca²⁺ /cAMP Intracellular Signalling Pathways in Clinical Pharmacology and Translational Medicine. *Clin Pharmacol Transl Med* 1-4.
- Errante PR, Caricati-Neto A, Bergantin LB (2017) Insights for the inhibition of cancer progression: Revisiting Ca²⁺ and cAMP signalling pathways. *Adv Cancer Prevention* 2: e103.
- Yoshida J, Ishibashi T, Nishio M (2007) G1 cell cycle arrest by amlodipine, a dihydropyridine Ca²⁺ channel blocker, in human epidermoid carcinoma A431 cells. *Biochem Pharmacol* 73: 943-953.
- Krouse AJ, Gray L, Macdonald T, McCray J (2015) Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study. *Assay Drug Dev Technol* 13: 650-653.
- Kim KH, Kim D, Park JY, Jung HJ, Cho YH, et al. (2015) NNC 55-0396, a T-type Ca²⁺ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1 α signal transduction. *J Mol Med (Berl)* 93: 499-509.
- Massimi M, Cardarelli S, Galli F, Giardi MF, Ragusa F, et al. (2017) Increase of Intracellular Cyclic AMP by PDE4 Inhibitors Affects HepG2 Cell Cycle Progression and Survival. *J Cell Biochem* 118: 1401-1411.